Preparation and characterization of a biodegradable drug targeting system for anticancer drug delivery: Microsphere-antibody conjugate

Journal of Drug Targeting

Volumn 13, Issue 3, 2005, Pages 151-159

  Muvaffak, Asli ^a,b   Gurhan, Ismet ^c   Gunduz, Ufuk ^b   Hasirci, Nesrin ^b  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^b MIDDLE EAST TECHNICAL UNIVERSITY   (Turkey)

^c EGE UNIVERSITY   (Turkey)

Author keywords

Cytotoxicity; Drug targeting; Gelatin microspheres anti BSA conjugate; Immunofluorescence

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; ALBUMIN ANTIBODY; ANTIBODY CONJUGATE; ANTINEOPLASTIC AGENT; DRUG CARRIER; FLUORESCEIN ISOTHIOCYANATE; FLUOROURACIL; GELATIN; GLUTARALDEHYDE; METHOTREXATE; MICROSPHERE;

ANTIGEN BINDING; ARTICLE; BIODEGRADABILITY; CANCER CELL CULTURE; CONCENTRATION (PARAMETERS); CONJUGATE; CONTROLLED STUDY; CROSS LINKING; CYTOTOXICITY; DRUG BINDING SITE; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG RELEASE; DRUG SYNTHESIS; DRUG TARGETING; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE TEST; IN VITRO STUDY; PRIORITY JOURNAL; SUSTAINED RELEASE PREPARATION;

ANTIBODIES; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CROSS-LINKING REAGENTS; DRUG DELIVERY SYSTEMS; DRUG STABILITY; EXCIPIENTS; FEMALE; FLUORESCEIN-5-ISOTHIOCYANATE; FLUORESCENT DYES; FLUOROURACIL; GELATIN; GLUTARAL; HUMANS; METHOTREXATE; MICROSCOPY, ELECTRON, SCANNING; MICROSCOPY, FLUORESCENCE; MICROSPHERES; PARTICLE SIZE; SERUM ALBUMIN, BOVINE;

EID: 18744389478     PISSN: 1061186X     EISSN: None     Source Type: Journal    
DOI: 10.1080/10611860400029069     Document Type: Article

References (29)

1. Babson AL, Winnick T. 1954. Protein transfer in tumour-bearing rats. Cancer Res 14:606-611.
2. Blair AH, Ghose TI. 1983. Linkage of cytotoxic agents to immunoglobulin. J Immunol Methods 59:29-143.
3. DiJoseph JF, Armellino DC, Boghaert ER, Khandke K, Dougher MM, Sridharan L, Kunz A, Hamann PR, Gorovits B, Udata C, et al. 2004. Antibody-targeted chemotherapy with CMC-544: A CD22-targeted immunoconjugate of calicheamicin for the treatment of B-lymphoid malignancies. Blood 103:1807-1814.
4. Forni F, Vandelli MA, Cameroni R. 1992. Influence of drug loading level on drug release and dynamic swelling of crosslinked gelatin microspheres. J Microencapsul 9:29-39.
5. Freshney RI. 2000. Culture of animal cells: A manual of basic technique. USA: Wiley-Liss Inc. p 329-331.
6. Ghose T, Blair AH. 1978. Antibody-linked cytotoxic agents in the treatment of cancer: Current status and future prospects. J Natl Cancer Inst 61:657-676.
7. Hanes J, Sills A, Zhao Z, Suh KW, Tyler B, Dimeco F, Brat DJ, Choti MA, Leong KW, Pardoll DM, Brem H. 2001. Controlled local delivery of interleukin-2 by biodegradable polymers protects animals from experimental brain tumours and liver tumours. Pharm Res 18:899-906.
8. Hebert C, Norris K, Sauk JJ. 2003. Targeting of human squamous carcinomas by SPA470-doxorubicin immunoconjugates. J Drug Target 11:101-107.
9. Jeyantthi R, Rao KP. 1989. Release characteristics of bleomycin, mitomycin C and 5-fluorouracil from gelatin microspheres. Int J Pharm 55:31-37.
10. Kratz F, Beyer U. 1998. Serum proteins as drug carriers of anticancer agents: A review. Drug Deliv 5:281-299.
11. Larhed A, Stertman L, Edvardsson E, Sjoholm I. 2004. Starch microparticles as oral vaccine adjuvant: Antigen-dependent uptake in mouse intestinal mucosa. J Drug Target 12:289-296.
12. Lee JM, Edwards HHL, Pereira CA, Samii SI. 1996. Crosslinking of tissue derived biomaterials in EDAC. J Mater Sci Mater Med 7:531-541.
13. Lopez JM, Imperial S, Valderrama R, Navarro S. 1993. An improved Bradford protein assay for collagen proteins. Clin Chim Acta 220:91-100.
14. Marois Y, Chakfe N, Deng X, Marois M, How T, King W, Guidoin R. 1995. Carbodiimide crosslinked gelatin: A new coating for porous polyester arterial prostheses. Biomaterials 16:1131-1139.
15. Masters JRW. 2000. Animal cell culture: A practical approach. Oxford, New York: Oxford University Press. p 183-192.
16. Muvaffak A. 2003. Controlled release systems for anticancer drugs and drug targeting in cancer therapy PhD thesis. Ankara, Turkey: Middle East Technical University.
17. Muvaffak A, Hasirci N. 2002. Controlled release of colchicine from glutaraldehyde crosslinked gelatin microspheres. Technol Health Care 10:347-350.
18. Muvaffak A, Hasirci N. 2003a. The use of antibodies in diagnosis and therapy of cancer. Adv Exp Med Biol 534:309-325.
19. Muvaffak A, Hasirci N. 2003b. Microsphere-antibody conjugate. Turkish Patent Office, Ankara, Turkey (no: 01787, patent pending).
20. Muvaffak A, Gurhan I, Hasirci N. 2004a. Cytotoxicity of 5-fluorouracil entrapped in gelatin microspheres. J Microencapsul 21:293-306.
21. Muvaffak A, Gurhan I, Hasirci N. 2004b. Prolonged cytotoxic effect of colchicine released from biodegradable microspheres. J Biomed Mat Res 71:295-304.
22. Nam SM, Kim HS, Ahn WS, Park YS. 1999. Sterically stabilized anti-G(M3), anti-Le(x) immunoliposomes: Targeting to B16BL6, HRT-18 cancer cells. Oncol Res 11:9-16.
23. Narayani R, Rao KP. 1996. Biodegradable microspheres using two different gelatin drug conjugates for the controlled delivery of methotrexate. Int J Pharm 128:261-268.
24. Osth K, Strindelius L, Larhed A, Ahlander A, Roomans GM, Sjoholm I, Bjork E. 2003. Uptake of ovalbumin-conjugated starch microparticles by pig respiratory nasal mucosa in vitro. J Drug Target 11:75-82.
25. Rao KP. 1995. Recent developments of collagen-based materials for medical applications and drug delivery system. J Biomater Sci Polym Ed 7:623-645.
26. Rhines LD, Sampath P, DiMeco F, Lawson HC, Tyler BM, Hanes J, Olivi A, Brem H. 2003. Local immunotherapy with interleukin-2 delivered from biodegradable polymer microspheres combined with interstitial chemotherapy: A novel treatment for experimental malignant glioma. Neurosurgery 52:872-879.
27. Stehle G, Sinn H, Wunder A, Schrenk HH, Stewart JCM, Hartung G, Maier-Borst W, Heene DL. 1997. Plasma protein (albumin) catabolism by the tumour itself-implications for tumour metabolism and the genesis of cachexia. Crit Rev Oncol Hematol 26:77-100.
28. Sugano M, Egilmez NK, Yokota SJ, Chen FA, Harding J, Huang SK, Bankert RB. 2000. Antibody targeting of doxorubicin-loaded liposomes suppresses the growth and metastatic spread of established human lung tumour xenografts in severe combined immunodeficient mice. Cancer Res 60:6942-6949.
29. Yuan F, Deilian M, Fukumura D, Berk DA, Torchilin VP, Jain RK. 1995. Vascular permeability in a human xenograft: Molecular size dependence and cut off size. Cancer Res 55:3752-3756.